Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.
Animals
Cell Line, Tumor
Cell Proliferation
Cell Transformation, Neoplastic
Female
Galectin 3
/ immunology
Gene Expression Regulation, Neoplastic
Humans
Immunoconjugates
/ immunology
Iodine Radioisotopes
Mice
Positron Emission Tomography Computed Tomography
Radioactive Tracers
Spheroids, Cellular
/ pathology
Symporters
/ metabolism
Thyroid Neoplasms
/ diagnostic imaging
124I
PET imaging
galectin-3
orthotopic models
thyroid tumor
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
09
08
2018
accepted:
10
10
2018
pubmed:
27
10
2018
medline:
31
3
2020
entrez:
27
10
2018
Statut:
ppublish
Résumé
Preoperative characterization of thyroid nodules is challenging since thyroid scintigraphy fails to distinguish between benign and malignant lesions. Galectin-3 (gal-3) is expressed in well-differentiated and in undifferentiated thyroid cancer types but not in normal thyrocytes and benign thyroid lesions. Herein, we aimed to validate gal-3 targeting as a specific method to detect non-radioiodine-avid thyroid cancer in thyroid orthotopic tumor models.
Identifiants
pubmed: 30361380
pii: jnumed.118.219105
doi: 10.2967/jnumed.118.219105
pmc: PMC6581231
doi:
Substances chimiques
Galectin 3
0
Immunoconjugates
0
Iodine Radioisotopes
0
Iodine-124
0
Radioactive Tracers
0
Symporters
0
sodium-iodide symporter
4XE5NDT4K1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
770-776Informations de copyright
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Lancet. 2001 May 26;357(9269):1644-50
pubmed: 11425367
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Endocrinol Metab. 2004 Feb;89(2):1006-9
pubmed: 14764827
World J Surg. 2004 Mar;28(3):271-6
pubmed: 14961204
J Nucl Med. 1992 Sep;33(9):1685-91
pubmed: 1517844
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Biotechnol Annu Rev. 2005;11:127-52
pubmed: 16216776
Lancet Oncol. 2008 Jun;9(6):543-9
pubmed: 18495537
PLoS One. 2008;3(11):e3768
pubmed: 19020658
Eur J Clin Invest. 2009 Aug;39(8):699-706
pubmed: 19601965
Endocrinology. 2012 Jun;153(6):2907-18
pubmed: 22510270
Pharmacol Ther. 2012 Sep;135(3):355-70
pubmed: 22750642
Theranostics. 2012;2(8):769-76
pubmed: 22916076
Nat Rev Clin Oncol. 2013 Sep;10(9):507-18
pubmed: 23881033
J Nucl Med. 2014 May;55(5):799-804
pubmed: 24627434
J Nucl Med. 2014 Dec;55(12):2032-7
pubmed: 25359880
J Cell Biochem. 2015 May;116(5):822-35
pubmed: 25530451
J Nucl Med. 2015 Nov;56(11):1690-6
pubmed: 26338896
JAMA Oncol. 2016 Aug 1;2(8):1023-9
pubmed: 27078145
JAMA Otolaryngol Head Neck Surg. 2016 Jul 1;142(7):709-11
pubmed: 27078686
Cancer Res. 2016 Jun 15;76(12):3583-92
pubmed: 27216181
J Surg Oncol. 2017 Jun;115(7):848-855
pubmed: 28205245
J Exp Med. 2017 Aug 7;214(8):2243-2255
pubmed: 28666979
Theranostics. 2017 Jun 15;7(9):2402-2416
pubmed: 28744323
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
J Immunol Methods. 1983 Nov 11;64(1-2):141-6
pubmed: 6644029
Cancer Res. 1995 Aug 1;55(15):3267-71
pubmed: 7542167
J Cancer Res Clin Oncol. 1996;122(10):603-12
pubmed: 8879258
Eur J Nucl Med. 1998 Feb;25(2):201-12
pubmed: 9473271